Kerala Ayurveda Reports Record Sales Amid Declining Profitability Challenges in December 2024

Kerala Ayurveda, a microcap player in the Pharmaceuticals & Drugs industry, has recently reported its financial results for the quarter ending December 2024. The evaluation changes indicate a notable shift in the company's score, which has seen a revision from 25 to -2 over the past three months. The financial results highlight some positive aspects for Kerala Ayurveda. The company achieved its highest quarterly net sales at Rs 31.13 crore, demonstrating consistent growth over the last five quarters. Additionally, the debt-equity ratio has reached its lowest point in the last five half-yearly periods at 1.77 times, reflecting a strategic reduction in borrowing relative to equity capital. Conversely, several challenges are evident in the financial performance. The profit after tax (PAT) has recorded a significant decline, landing at Rs -2.89 crore, which marks a stark contrast to the average PAT of Rs 0.66 crore from the previous four quarters. Other metrics, including operating profit and profit before tax, have also reached their lowest levels in recent quarters, indicating difficulties in managing operational efficiency and interest obligations. Overall, Kerala Ayurveda's financial results reveal a complex landscape of growth in sales juxtaposed with significant challenges in profitability and operational performance. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.